43 articles
The following presentation titled ‘Pharma Patents and Drug Prices’ was delivered by Dr. Kalyan C. Kankanala (Managing Partner, BananaIP Counsels, Bangalore) on 5th January, 2016 at the conference…
This post examines Pfizer’s patent application on a known substance and the Indian Patent Office’s refusal in light of Section 3d and the Novartis decision. It discusses whether…
This post analyses the Indian Patent Office’s rejection of Pfizer’s Tofacitinib patent under Section 3(d). The decision addresses issues of novelty, inventive step, and the requirement for evidence…